The industry and its issues, from editor-in-chief William Looney.
February 1, 2008
By:
Patrick Clinton
New from Pharm Exec: a blog, expanded tech and deals coverage, and a new awards program for emerging pharma leaders
|
|
January 1, 2008
By:
Patrick Clinton
A new report says FDA is desperately behind on science. At last, a critique we can actually do something about. But will we?
|
|
December 1, 2007
By:
Patrick Clinton
For several decades, pharma got the message that promotion could make consumers want to use new drugs. The system didn't work with Pfizer's Exubera. That's surprising news, but is it bad news?
|
November 1, 2007
By:
Patrick Clinton
A hospital safety expert says it's now possible to completely eliminate certain adverse events. Pharma can't claim the same yet, but is it time for us to start imagining a time when we can "benchmark perfection"?
|
October 1, 2007
By:
Patrick Clinton
FDA has just premiered a new newsletter on drug safety. There's just one little problem....
|
September 1, 2007
By:
Patrick Clinton
In this issue, a longtime contributor to this magazine, former FDA official, and generally thoughtful, knowledgeable person concludes his excellent three-part series on drug safety with a look at how risk is communicated to patients and doctors. It's a fine, detailed, subtle piece of work, and I recommend it to you. (See "Failure to Communicate".)
|
July 30, 2007
By:
Patrick Clinton
Of all pharma's marketing tactics, the hardest to swallow was "marketing the spread." This was a scheme developed in the 1990s for physician-administered drugs (PADs)—injectables, cancer drugs, etc., which are purchased from wholesalers by physicians and reimbursed by Medicare or third-party payers. Until recently, reimbursement was based on Average Wholesale Price (AWP). This sounds like it ought to mean the average of prices paid to wholesalers, but in practice, it was always closer to sticker price. Manufacturers discovered that they could give physicians a tidy bonus by creating a spread between AWP and what docs paid.
|
|
July 3, 2007
By:
Patrick Clinton
The Acomplia story isn't ending. It's just beginning. Get ready to see what happens when a much-desired drug is marketed by people accountable to no one.
|
|
June 1, 2007
By:
Patrick Clinton
It's not FDA's job to make doctors and patients take more responsibility for using drugs wisely. But whose job is it? Really, whose?
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
